Podcasts and Further Resources
Our series ‘Prof Talks’ dives into the science behind the Attomarker COVID Antibody Spectrum Test as well as covering topics such as ‘Hyper-immunity’ and ‘Children and Long COVID’.
We also run additional episodes with clinicians such as Dr Ben Sinclair covering the latest research in Long COVID recovery: turning the science into medicine.
Links to podcasts are available on this website and on our
YouTube Channel.
Professor Shaw and Attomarker also feature in other podcasts, programmes and articles, including:
Listen to our latest webinar with Prof Andrew Shaw and Dr Deb Giorgi-Guarnieri, based in the US. Dr Deb G-G has special interest in treating psychiatric complications of Long COVID and Vaccine Injury.
View our latest Blogs
Confronting Long COVID: The Persistent Virus Hypothesis
The Immune Response to SARS-CoV-2 and Long COVID Long COVID is currently reported to affect as many as one in five individuals who have had a COVID infection in the UK, with each new SARS-CoV-2 infection adding to the risk burden of developing the debilitating...
Attomarker To Lead New Medical Intervention to Explore Monoclonal Antibody Treatment for Long COVID
EXETER, UK – 4 April 2025 – Attomarker, a leader in rapid diagnostic technology, today announced its plans for a new study evaluating the use of AstraZeneca’s monoclonal antibody, Sipavibart (Kavigale), as a potential treatment for long COVID patients. Long COVID...
International Long COVID Awareness Day 2025
International Long COVID Awareness Day 2025 Five Years On, Long COVID Patients Are Still Being Left Behind On 15th March we mark five years since the start of the pandemic and with it, International Long COVID Awareness Day. While COVID-19 may have faded from...
Treating Long Covid: The Persistent Virus Hypothesis
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: Visit our clinics Elimination of a SARS-CoV-2 infection requires both antibody and T cells for complete clearance of the coronavirus from the localised infection site. Systemic...
Attomarker has been selected as one of the companies by Innovate UK
Attomarker has been selected as one of the companies by Innovate UK for the following category: GBIP in Hyderabad and Bangalore, India - Antimicrobial Resistance, diagnostics and therapeutics Why India? India has recognised the importance of AMR, and the Indian...
Attomarker is Revolutionising Diagnostic Technology and the Potential of Big Data
We are working with partners to enable early medical intervention for longer, healthier lives for humans and animals. Attomarker Ltd is offering an Advanced Subscription Agreement funding round to support product development, regulatory and roll out. A full set...
Treating Long Covid: The Persistent Virus Hypothesis
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: longcovid@re-cognitionhealth.comElimination of a SARS-CoV-2 infection requires both antibody and T cells for complete clearance of the coronavirus from the localised infection site. Systemic...
Long Covid – can we weaken its grip?
#LongCovid is now affecting over 2 million people in the UK, a "mass disabling event" harming health and livelihoods. In the US, where it is reported over 20 million are afflicted with the condition, Long Covid is being described as the “next public health disaster”...
Back to School: COVID predicted to cause further disruption to education
Schools have returned About a month ago, schools returned for the 2022/23 academic year. This will expose many teachers and students to viruses brought home from summer holidays and socialising with family and friends. These viruses include the new Omicron variants of...
